The top barrier to AI adoption among pharma commercial leaders is compliance uncertainty, and the fix may be governance that evaluates one use case at a time.
News|Articles|March 4, 2026
Technological Renaissance: AI’s Integration into the Pharmaceutical Industry
As AI rapidly reshapes drug development and clinical operations, industry leaders say transparency, governance, and strong data foundations will determine whether the technology accelerates innovation or stalls under regulatory and operational pressure.
Advertisement
Advertisement
Artificial intelligence, once viewed as a distant promise within the pharmaceutical industry, has accelerated its way into operational reality.
Related to this article
Brox.AI's co-founder and CEO on why telling an AI to pretend to be a doctor isn’t the same as cloning one — and why that distinction matters for pharma.
As AI accelerates drug discovery, the industry’s next challenge is building a connected, standards-based data infrastructure capable of supporting it through clinical development.
Brock.AI’s Hamish Brocklebank on recruiting 8% of all US pancreatic cancer prescribers — paying $2,000 an hour, offering equity, and triple opt-in consent.
The infrastructure decisions companies make today could determine how quickly they capitalize on new computational capabilities
Brox.AI’s Hamish Brocklebank on three levels of digital clone use cases — from HCP content testing and GLP-1 price sensitivity modeling to simulating physician adoption after FDA approval.
Brox.AI’s Hamish Brocklebank on the three approaches to digital twins in pharma — and why only one-to-one clones of real individuals deliver true accuracy.
Pathos AI launches multi-year collaborations to build an AI-driven dataset for Alzheimer’s and other neurological diseases.
Advertisement
Advertisement